It would be a stretch to call it an offer she couldn’t refuse, but in the end what choice did Rep. Niki Tsongas (D-Mass.) have but to consider the pleas of the men in her Capitol Hill office last Thursday?
Tsongas represents a stretch of Massachusetts that runs from the edge of Natick to the tip of New Hampshire and includes the lion’s share of the I-495 beltway, where you can’t throw a trocar without hitting a company that either makes a medical device or services a medical device company.
Revenues during the 3 months ended March 31 grew 11.6% to $90.4 million, compared with $81 million during the same period last year, driven by some big boosts in regional sales.
Netanya, Israel-based Ventor is developing an aortic replacement valve called the Engager. Medtronic bought the company for $325 million 3 years ago.
The cardiac rhythm management market is "about as bad as it has ever been," according to an analyst with Gabelli & Co., due in part to headwinds from a federal probe and a negative journal article.
The National Venture Capital Assn. is spearheading a drive to get a bill through the U.S. Senate that would make it easier for small companies to raise money by going public.
The "IPO On Ramp" measure would ease the regulatory requirements for IPOs and temporarily reduce the reporting burdens imposed by the Sarbanes-Oxley Act.
Edwards Lifesciences (NYSE:EW) said it will re-state its financial results for the first 3 quarters of 2011, “due to certain technical errors in the balance sheets and cash flow statements for these interim periods.”
The Irvine, Calif.-based heart valve maker said the errors involve the mis-statement of short-term investments as cash & equivalents, plus the way it treated tax benefits from stock plans.